Table 2.
Univariate analysis |
Multivariate analysis |
||||
---|---|---|---|---|---|
Remission (n = 45) | Nonremission (n = 40) | p | Odds ratio (95% CI) | p | |
Male | 27 | 21 | 0.487 | — | |
Age | 34.49 ± 12.65 | 31.45 ± 13.82 | 0.291 | — | |
Duration (months) | 51.02 ± 45.12 | 50.73 ± 44.43 | 0.975 | — | |
Smoke | 6 | 2 | 0.207 | — | |
Surgery | 21 | 13 | 0.201 | — | |
Maintenance therapy | — | ||||
None | 24 | 22 | 1 | ||
Mesalazine | 7 | 5 | 0.704 | ||
Azathioprine | 7 | 8 | 0.711 | ||
Thalidomide | 2 | 2 | 0.933 | ||
Sulfasalazine | 4 | 1 | 0.261 | ||
Tripterygium | 1 | 2 | 0.536 | ||
BMI | 18.6 ± 2.72 | 17.33 ± 2.9 | 0.032 | 0.905 (0.674–1.214) | 0.506 |
B | — | ||||
1 | 10 | 12 | 1 | ||
2 | 17 | 13 | 0.425 | ||
3 | 18 | 15 | 0.509 | ||
P | 16 | 14 | 0.957 | — | |
Pancolitis | 6 | 13 | <0.001 | 4.896 (1.223–19.607) | 0.025 |
Feature of lesion | 2.320 (1.143–4.708) | 0.020 | |||
Aphtha ulcers | 29 | 8 | 1 | ||
Fissuring ulcers | 7 | 13 | 0.526 | ||
Stricturing | 7 | 20 | <0.001 | ||
Stricturing and ulcers | 2 | 9 | 0.001 | ||
SES-CD | 4.56 ± 3.25 | 8.80 ± 4.28 | <0.001 | 1.892 (1.086–4.117) | 0.014 |
CRP (mg/l) | 43.0 ± 37.75 | 58.85 ± 54.9 | 0.130 | 1.014 (1.011–1.030) | 0.041 |
ESR (mm/h) | 41.18 ± 25.80 | 36.38 ± 26.59 | 0.403 | — | |
Alb (g/l) | 36.89 ± 5.91 | 35.45 ± 6.74 | 0.311 | — | |
Pre-Alb (g/l) | 136.04 ± 70.86 | 128.4 ± 71.15 | 0.620 | — | |
∆Pre-Alb (g/l) | 37.58 ± 73.56 | −4.40 ± 59.68 | 0.008 | 0.983 (0.972–0.995) | 0.005 |
LBMI (kg/m2) | 8.38 ± 1.22 | 7.7 ± 1.47 | 0.014 | 0.377 (0.206–0.689) | 0.002 |
Data shown as mean ± SD and n (%).
Alb, albumin; BMI, body mass index; B1, non-stricturing non-penetrating; B2, structuring; B3, penetrating; cCD, isolated colonic Crohn’s disease; CI, confidence interval; CRP, C-reactive protein; EEN, exclusive enteral nutrition; ESR, erythrocyte sedimentation rate; HBI, Harvey-Bradshaw Index; LBMI, lean body mass index; P, perianal lesions; Pre-Alb, prealbumin; SES-CD, simple endoscopic score for Crohn’s disease; SD, standard deviation.